Veliparib added onto frontline chemotherapy followed by veliparib maintenance monotherapy (veliparib throughout) significantly prolonged progression-free survival (PFS) in women with newly diagnosed high-grade serous ovarian carcinoma, the phase III placebo-controlled VELIA/GOG-3005 trial has shown.
Circulating tumour DNA (ctDNA) holds strong prognostic value in colorectal cancer patients, according to a new study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019). CtDNA may also help determine the optimum treatment intensity.
Pembrolizumab, used in both neoadjuvant and adjuvant settings, significantly improves pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC), according to late-breaking results of the phase III KEYNOTE-522 trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.
The use and choice of chemotherapy significantly impact overall survival (OS) of patients with sarcoma, according to a population-based retrospective cohort study involving more than 3,000 patients treated in Hong Kong.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.